Transarterial chemoembolization plus sorafenib: A sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: A randomized clinical trial

Oncologist

Volumn 17, Issue 3, 2012, Pages 359-366

  Sansonno, Domenico ^a   Lauletta, Gianfranco ^a   Russi, Sabino ^a   Conteduca, Vincenza ^a   Sansonno, Loredana ^b   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Liver cirrhosis; Sorafenib; Time to progression

Indexed keywords

DOXORUBICIN; GELATIN SPONGE; LIDOCAINE; MITOMYCIN C; PLACEBO; SORAFENIB;

ADJUVANT THERAPY; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER RELAPSE; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEPATITIS C; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR NECROSIS;

AGED; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; PYRIDINES;

EID: 84859381338     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0313     Document Type: Article

References (37)

1. Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. The Oncologist 2010;15(suppl 4):23-33.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
3. Park YN, Roncalli M. Large liver cell dysplasia: A controversial entity. J Hepatol 2006;45:734-743.
4. Sansonno D, Cornacchiulo V, Racanelli V et al. In situ simultaneous detection of hepatitis C virus RNA and hepatitis C virus-related antigens in hepatocellular carcinoma. Cancer 1997;80:22-33.
5. Shimizu M, Sakai H, Moriwaki H. Chemoprevention of hepatocellular carcinoma by acyclic retinoid. Front Biosci 2011;16:759-769.
6. Doskali M, Tanaka Y, Ohira M et al. Possibility of adoptive immunotherapy with peripheral bloodderived CD3 CD56 and CD3 CD56 cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity. J Immunother 2011;34: 129-138.
7. Rahbari NN, Mehrabi A, Mollberg NM et al. Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg 2011;253:453-469.
8. Olioso P, Giancola R, Riti M et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial. Hematol Oncol 2009;27:130-139.
9. Ono T, Yamanoi A, Nazmy El Assal O et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: Metaanalysis of three randomized controlled trials. Cancer 2001;91:2378-2385.
10. Ono T, Nagasue N, Kohno H et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: A prospective randomized study. Semin Oncol 1997; 24(suppl 6):S6-18-S6-25.
11. Tang TC, Man S, Lee CR et al. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia 2010;12:264-274.
12. Hasegawa K, Takayama T, Ijichi M et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial. Hepatology 2006;44: 891-895.
13. Chang YS, Adnane J, Trail PA et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-574.
14. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
15. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10: 25-34.
16. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;125(suppl):S17-S188.
17. Sergio A, Cristofori C, Cardin R et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914-921.
18. Shim JH, Park JW, Kim JH et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008;99:2037-2044.
19. Cabrera R, Pannu DS, Caridi J et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011;34:205-213.
20. Italian Medicines Agency (AIFA) Research & Development Working Group. Feasibility and challenges of independent research on drugs: The Italian medicines agency (AIFA) experience. Eur J Clin Invest 2010;40:69-86.
21. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
22. European Medicines Agency. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Topic E 6: Guideline for Good Clinical Practice. Available at http://www.emea. europa.eu/pdfs/human/ich/013595en.pdf, accessed September 25, 2008.
23. World Medical Association Declaration of Helsinki. Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects, Adopted by the 18th World Medical Assembly, Helsinki, Finland, June, Amended by 48th General Assembly, Somerset West, South Africa, 1996. Available at http://www.wma.net/en/30publications/ 10policies/b3/17c.pdf, accessed September 25, 2008.
24. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004;127(suppl 1):S133-S143.
25. Takayasu K, Arii S, Matsuo N et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000;175: 699-704.
26. Kanematsu T, Furuta T, Takenaka K et al. A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989;10:98-102.
27. Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: A new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8:1743-1749.
28. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
29. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
30. Sasaki Y, Yamada T, Tanaka H et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis Bor hepatitis C-related hepatocellular carcinoma. Ann Surg 2006;244:771-780.
31. Heathcote EJ. Prevention of hepatitis C virusrelated hepatocellular carcinoma. Gastroenterology 2004;127(suppl 1):S294-S302.
32. Schmidt C, Marsh JW. Molecular signature for HCC: Role in predicting outcomes after liver transplant and selection for potential adjuvant treatment. Curr Opin Organ Transplant 2010;15:277-282.
33. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011;30:1969-1983.
34. Castello G, Costantini S, Scala S. Targeting the inflammation in HCV-associated hepatocellular carcinoma: A role in the prevention and treatment. J Transl Med 2010;8:109-120.
35. Hoshida Y, Toffanin S, Lachenmayer A et al. Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements. Semin Liver Dis 2010;30:35-51.
36. Dufour JF, Hoppe H, Heim MH et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocel lular carcinoma: Results of a phase I study. The Oncologist 2010;15:1198-1204.
37. Pawlik TM, Reyes DK, Cosgrove D et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29: 3960-3967.